| Bioactivity | Relebactam is a diazabicyclooctane inhibitor with activity against a wide spectrum of β-lactamases, including class A (extended-spectrum β-lactamases and KPC) and class C (AmpC) enzymes. Relebactam shows antibacterial activity[1]. | ||||||||||||
| Invitro | Relebactam combine with Imipenem demonstrates activity against KPC-producing Enterobacteriaceae and multidrug-resistant P. aeruginosa[1].Relebactam shows limited inhibition of Class D-producing bacteria and has antipseudomonal activity[2]. | ||||||||||||
| Name | Relebactam | ||||||||||||
| CAS | 1174018-99-5 | ||||||||||||
| Formula | C12H20N4O6S | ||||||||||||
| Molar Mass | 348.38 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Lapuebla A, et al. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City. Antimicrob Agents Chemother. 2015 Aug;59(8):5029-31. [2]. Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015 Nov;46(5):483-93. |